Supplemental Funding

Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations with the NCI-supported Drug Resistance and Sensitivity Network (DRSN)

NOT-CA-20-014

As a part of the Cancer Moonshot Initiative, the National Cancer Institute (NCI) funded the Drug Resistance and Sensitivity Network (DRSN), a collaborative network of centers of excellence (based on U54 cooperative agreement awards issued in response to the RFA-CA-17-009), which is focused on using advanced techniques and models to accelerate understanding of issues related to cancer resistance or extreme sensitivity to anticancer agents. Investigators in the DRSN are working to solve issues of cancer drug resistance as part of the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials. With planned use of funds available from the Cancer Moonshot Initiative, and in pursuant of the NIH's interest in accelerating cancer research, the NCI invites, through PA-18-591 in conjunction with this Notice of Special Interest (NOSI), the submission of request for administrative supplement to active NCI-funded grants and cooperative agreements. The goal is to encourage new interdisciplinary collaborations between outside (non-DSRN-supported) investigators and DRSN U54-supported investigators to perform research within the scientific scope(s) of their active parent grant(s) and/or cooperative agreement award(s). These collaborations between applicants and a U54 DRSN group are expected to lead to improved pre-clinical evaluations of novel discoveries in cancer drug resistance that could ultimately be tested in NCI-sponsored clinical trials. Non-DRSN investigators can also propose to conduct collaborative studies to advance mechanistic validation of their discoveries in cancer drug resistance using the cancer drug resistance resources of the DSRN. Results from the mechanistic studies fostered through this opportunity could feasibly lead to clinical validations of concepts that identify and circumvent cancer drug resistance in patients.

In advance of preparation and submission of an administrative supplement request (i.e., application), inquiries from eligible awardee-applicants in response to this Notice (NOT-CA-20-014), the examination of the related funding opportunity through PA-18-591, and discussion with appropriate NCI staff persons about this NOSI initiative are encouraged.

Please direct all inquiries to:

Kim Witherspoon
National Cancer Institute (NCI)
Telephone: 240-276-6141
Email: withersk@ctep.nci.nih.gov

Percy Ivy, M.D.
National Cancer Institute (NCI)
Telephone: 240-276-6565
Email: ivyp@ctep.nci.nih.gov




Notice of Special Interest: Administrative Supplements for Activities to Promote Human Immune-Representing Oncology Models

NOT-CA-19-028

Through funds available from the Cancer Moonshot InitiativeSM, and pursuant to the NIH interest in advancing human tissue models that do not rely on human fetal tissue (NOT-OD-19-042), the National Cancer Institute (NCI) is inviting applications for administrative supplements to improve representation of the human immune system in ongoing cancer modeling development projects that can be utilized in immuno-oncology research.

NCI supports a number of oncology model development efforts through a variety of mechanisms spanning both in vitro and in vivo model systems. Through funds available from the Cancer Moonshot Initiative, NCI is announcing the opportunity for investigators with relevant active research project grants and cooperative agreements to submit administrative supplement requests according to PA-18-591, to advance either an in vivo or in vitro model system to more closely recapitulate aspects of the human immune system in the context of the tumor microenvironment, in a manner that directly supports immuno-oncology research. Specifically, the NCI seeks to support projects that replace the use of human fetal tissue to model the tumor microenvironment with a more faithful representation of the human immune system.

In advance of preparation and submission of an administrative supplement request (i.e., application), inquiries from eligible awardee-applicants in response to this Notice (through PA-18-591), the related funding opportunity through PA-18-591, and any potential requests to appropriate NCI staff persons are encouraged.

For more details and important submission instructions please visit the Notice at: NOT-CA-19-028

All requests, regardless of the parent award funding mechanism, must be received by 5:00 PM local time on June 3, 2019, for funding in FY 2019

Please direct all inquiries to:

Tony Dickherber, Ph.D.
National Cancer Institute (NCI)
Telephone: 301-547-9980
Email: anthony.dickherber@nih.gov